Alnylam Pharmaceuticals Reports Q1 2026 Financials
Ticker: ALNY · Form: 8-K · Filed: Apr 30, 2026 · CIK: 0001178670
| Field | Detail |
|---|---|
| Company | Alnylam Pharmaceuticals, Inc. (ALNY) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-results
Related Tickers: ALNY
TL;DR
ALNY dropped Q1 earnings release on 4/30/26 - check the numbers!
AI Summary
On April 30, 2026, Alnylam Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and condition for the period ending April 30, 2026. The filing includes the company's earnings release for the first quarter of 2026.
Why It Matters
This filing provides investors with the latest financial performance data for Alnylam Pharmaceuticals, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not introduce new risks.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer of the 8-K report
- 0001178670 (company) — CIK number for Alnylam Pharmaceuticals, Inc.
- 2026-04-30 (date) — Period of Report and Filing Date
FAQ
What specific financial results are detailed in the filing?
The filing includes the company's earnings release for the first quarter of 2026, which contains specific financial results and condition details.
What is the filing date of this 8-K report?
The filing date of this 8-K report is April 30, 2026.
What are the main items covered in this 8-K filing?
This 8-K filing covers Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Where is Alnylam Pharmaceuticals, Inc. headquartered?
Alnylam Pharmaceuticals, Inc. is located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge MA 02142.
What is the CIK number for Alnylam Pharmaceuticals, Inc.?
The CIK number for Alnylam Pharmaceuticals, Inc. is 0001178670.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2026 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).